- Sjöström J, Alfthan H, Joensuu H, Stenman U-H, Lundin J, Blomqvist C. Serum tumour markers CA 15-3, TPA, TPS, hCG and TATI in monitoring chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest 2001; 61: 431-42.
- Kricka LJ. Interferences in immunoassays - still a threat. Clin Chem 2000; 46: 1037-8.
- Cole LA, Shahabi S, Butler SA, Mitchell H, Newlands ES, Behrman HR, Verrill HL. Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases. Clin Chem 2001; 47: 308-15.
- Stamey TA. Preoperative serum prostate-specific antigen below 10 µg/L predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem 2001; 47: 631-4.
- Fosså SD, Eri LM, Skovlund E, Tveter K, Vatten L. No randomised trial of prostate cancer screening in Norway. Lancet Oncol. In press.
- Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958-60.
- Klepp O. Serum tumour markers in testicular and extragonadal germ cell malignancies. Scand J Clin Lab Invest 1991; 51: Suppl 206: 28-41.
- Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem 2001; 47: 624-30.
- Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society for Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
- Loprinzi CL, Hayes D, Smith T. Doc, shouldn't we be getting some tests? Art of oncology: When the tumor is not the target. J Clin Oncol 2000; 18:2345-8.
Scandinavian Journal of Clinical and Laboratory Investigation
Volume 61, 2001 - Issue 6